Sysmex (OTCMKTS:SSMXY) Shares Gap Up – What’s Next?

Sysmex Corporation ADR (OTCMKTS:SSMXY) shares gapped up before the market opened on Friday . The stock had previously closed at $9.43, but opened at $10.01. Sysmex shares last traded at $10.01, with a volume of 511 shares traded.

Wall Street Analyst Weigh In

Separately, Zacks Research downgraded shares of Sysmex from a “hold” rating to a “strong sell” rating in a research note on Tuesday. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold”.

Sysmex Stock Performance

The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.46 and a current ratio of 3.26. The company has a market cap of $6.28 billion, a P/E ratio of 26.26 and a beta of 1.07. The stock’s fifty day moving average price is $8.93 and its two-hundred day moving average price is $9.07.

Sysmex (OTCMKTS:SSMXY) last announced its quarterly earnings data on Thursday, May 14th. The company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). Sysmex had a net margin of 7.13% and a return on equity of 7.23%. The firm had revenue of $877.92 million during the quarter, compared to the consensus estimate of $862.45 million. Sysmex has set its FY 2026 guidance at 0.370-0.370 EPS. As a group, equities analysts predict that Sysmex Corporation ADR will post 0.42 earnings per share for the current year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.